Intellia appoints Brian Goff to board; former Alexion commercial executive

Intellia Therapeutics, Inc.

Appointed as Class I director effective June 13, 2024; term through 2026 annual meeting.
Goff is CEO of Agios Pharmaceuticals; over 30 years biopharma commercial experience including EVP at Alexion.
Received option for 22,297 shares at $25.96 and 15,409 RSUs, vesting over three years.
Appointed to Compensation and Talent Development Committee; independent under Nasdaq rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brian Goff

Class I Director

NTLA · Intellia Therapeutics, Inc.

Effective: 2024-06-13
Filed: June 14, 2024, 7:59 PM ET

On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Goff was appointed as Class I Director at Intellia Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-073709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.